{"id":607,"date":"2026-02-05T10:59:25","date_gmt":"2026-02-05T09:59:25","guid":{"rendered":"https:\/\/studienportal-gyn.de\/new-findings-on-the-treatment-of-platinum-resistant-ovarian-cancer-results-of-the-rosella-study\/"},"modified":"2026-03-05T16:49:16","modified_gmt":"2026-03-05T15:49:16","slug":"new-findings-on-the-treatment-of-platinum-resistant-ovarian-cancer-results-of-the-rosella-study","status":"publish","type":"post","link":"https:\/\/studienportal-gyn.de\/en\/new-findings-on-the-treatment-of-platinum-resistant-ovarian-cancer-results-of-the-rosella-study\/","title":{"rendered":"New findings on the treatment of platinum-resistant ovarian cancer &#8211; results of the ROSELLA study"},"content":{"rendered":"\t\t<div data-elementor-type=\"wp-post\" data-elementor-id=\"607\" class=\"elementor elementor-607 elementor-403\">\n\t\t\t\t<div class=\"elementor-element elementor-element-80906d6 e-flex e-con-boxed e-con e-parent\" data-id=\"80906d6\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6678a14 elementor-widget elementor-widget-heading\" data-id=\"6678a14\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"heading.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t<h1 class=\"elementor-heading-title elementor-size-default\"><strong>New findings on the treatment of platinum-resistant <br>ovarian cancer<\/strong> <span>- Results of the ROSELLA study<\/span><\/h1>\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<div class=\"elementor-element elementor-element-e7a1356 elementor-widget elementor-widget-text-editor\" data-id=\"e7a1356\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p>At the end of January, the pharmaceutical company Corcept Therapeutics published a press release on the positive results of the ROSELLA study!<\/p><p data-start=\"310\" data-end=\"622\">This study investigated whether the combination of the drug <strong data-start=\"476\" data-end=\"492\">Relacorilant<\/strong> and the chemotherapy <strong data-start=\"515\" data-end=\"533\">nab-paclitaxel<\/strong> can improve the survival of patients with <strong data-start=\"569\" data-end=\"605\">platinum-resistant ovarian cancer<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-86f459b e-flex e-con-boxed e-con e-parent\" data-id=\"86f459b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-6ae4a54 elementor-widget elementor-widget-text-editor\" data-id=\"6ae4a54\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<h3 data-start=\"661\" data-end=\"924\">What was the study about?<\/h3><p data-start=\"661\" data-end=\"924\">Platinum-resistant ovarian cancer means that the tumor has continued to grow despite platinum-based chemotherapy and only responds to a limited extent to standard therapies. Such patients often have a poor prognosis and only limited treatment options. <\/p><p data-start=\"926\" data-end=\"1005\">In the ROSELLA study, <strong data-start=\"955\" data-end=\"975\">381 patients<\/strong> worldwide were randomly divided into two groups:<\/p><ul><li data-start=\"1008\" data-end=\"1079\">One group received <span style=\"color: #c31622;\"><strong data-start=\"1028\" data-end=\"1053\">nab-paclitaxel alone<\/strong><\/span> (standard chemotherapy),<\/li><li data-start=\"1008\" data-end=\"1079\">the other <span style=\"color: #c31622;\"><strong data-start=\"1093\" data-end=\"1129\">nab-Paclitaxel plus Relacorilant<\/strong><\/span>.<\/li><\/ul>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-bcaf64b e-flex e-con-boxed e-con e-parent\" data-id=\"bcaf64b\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-edd25e2 elementor-widget elementor-widget-text-editor\" data-id=\"edd25e2\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p data-start=\"1169\" data-end=\"1448\"> <\/p><h3 class=\"elementor-heading-title elementor-size-default elementor-inline-editing pen\" style=\"margin-top: 1.71429rem; margin-bottom: 1.71429rem; font-size: 16.8px; line-height: 1.84615; color: #c41522;\" data-elementor-setting-key=\"title\" data-pen-placeholder=\"Eingabe hier...\">What did the study show?<\/h3><p data-start=\"1169\" data-end=\"1448\"><strong data-start=\"1172\" data-end=\"1204\">1. lower risk of death<\/strong><br data-start=\"1204\" data-end=\"1207\">Patients who received Relacorilant in addition to chemotherapy had a <strong data-start=\"1289\" data-end=\"1329\">35% lower risk of death<\/strong> than those who received chemotherapy alone. This means that the new combination significantly prolonged <strong data-start=\"1419\" data-end=\"1438\">overall survival<\/strong>. <\/p><p data-start=\"1450\" data-end=\"1642\"><strong data-start=\"1453\" data-end=\"1482\">2. longer survival time<\/strong><br data-start=\"1482\" data-end=\"1485\">On average, patients with Relacorilant lived for 16.0 months compared to 11.9 months with chemotherapy alone &#8211; i.e. around <strong data-start=\"1622\" data-end=\"1641\">4 months longer<\/strong>.<\/p><p data-start=\"1644\" data-end=\"1865\"><strong data-start=\"1647\" data-end=\"1691\">3. better progression-free survival<\/strong><br data-start=\"1691\" data-end=\"1694\">It has previously been shown that the combination also improves the time until the disease progresses &#8211; i.e. the period in which tumors do not grow any further.<\/p><p data-start=\"1867\" data-end=\"2163\"><strong>4. well tolerated<\/strong><br data-start=\"1892\" data-end=\"1895\">Important: The combination was well tolerated and severe <strong>side effects<\/strong> <strong data-start=\"1979\" data-end=\"2001\">did not occur more frequently<\/strong> than with chemotherapy alone. This means that Relacorilant brings its benefits without noticeably worsening safety for patients. <\/p><p data-start=\"2165\" data-end=\"2437\"><strong data-start=\"2168\" data-end=\"2204\">5. no biomarker restriction<\/strong><br data-start=\"2204\" data-end=\"2207\">In contrast to some other therapies, it was not necessary to select patients according to a specific tumor biomarker in this study &#8211; the benefits of the therapy were <strong>independent of certain tumor characteristics<\/strong>.<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t<div class=\"elementor-element elementor-element-daf949f e-flex e-con-boxed e-con e-parent\" data-id=\"daf949f\" data-element_type=\"container\" data-e-type=\"container\">\n\t\t\t\t\t<div class=\"e-con-inner\">\n\t\t\t\t<div class=\"elementor-element elementor-element-fbc7a53 elementor-widget elementor-widget-text-editor\" data-id=\"fbc7a53\" data-element_type=\"widget\" data-e-type=\"widget\" data-widget_type=\"text-editor.default\">\n\t\t\t\t<div class=\"elementor-widget-container\">\n\t\t\t\t\t\t\t\t\t<p data-start=\"2498\" data-end=\"2784\"> <\/p><h3 class=\"elementor-heading-title elementor-size-default elementor-inline-editing pen\" style=\"margin-top: 1.71429rem; margin-bottom: 1.71429rem; font-size: 16.8px; line-height: 1.84615; color: #c41522;\" data-elementor-setting-key=\"title\" data-pen-placeholder=\"Eingabe hier...\">What does this mean for patients in Germany?<\/h3><p data-start=\"2498\" data-end=\"2784\"><strong data-start=\"2501\" data-end=\"2551\">Promising new treatment option in sight<\/strong><br data-start=\"2551\" data-end=\"2554\">The results are particularly important because they show for the first time that an additional substance not only delays progression but also prolongs overall survival &#8211; without additional safety issues.<\/p><p data-start=\"2786\" data-end=\"3192\"><strong data-start=\"2789\" data-end=\"2825\">Regulatory submissions currently underway<\/strong><br data-start=\"2825\" data-end=\"2828\">&#8211; In the US, the Food and Drug Administration (FDA) is currently reviewing Corcept&#8217;s application for approval of Relacorilant for platinum-resistant ovarian cancer; a result is expected by July 11, 2026.<br data-start=\"3043\" data-end=\"3046\">&#8211; In Europe &#8211; including Germany &#8211; the application is also currently being evaluated by the European Medicines Agency (EMA).<\/p><p data-start=\"3194\" data-end=\"3477\"><strong data-start=\"3197\" data-end=\"3257\">Until approval, it will not remain a standard in Germany<\/strong><br data-start=\"3257\" data-end=\"3260\">Until Relacorilant is officially approved, this combination is <strong data-start=\"3335\" data-end=\"3390\">not yet part of the regular treatment guidelines<\/strong> in Germany. But the current data are an important step in this direction. <\/p><p><strong>Source:<\/strong> <a href=\"https:\/\/ir.corcept.com\/news-releases\/news-release-details\/overall-survival-primary-endpoint-met-corcepts-pivotal-phase-3\/\" target=\"_blank\" rel=\"noopener\">Corcept press release<\/a> (the article is in English)<\/p>\t\t\t\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t\t\t<\/div>\n\t\t","protected":false},"excerpt":{"rendered":"<p>New findings on the treatment of platinum-resistant ovarian cancer &#8211; Results of the ROSELLA study At the end of January, the pharmaceutical company Corcept Therapeutics published a press release on the positive results of the ROSELLA study! This study investigated whether the combination of the drug Relacorilant and the chemotherapy nab-paclitaxel can improve the survival [&hellip;]<\/p>\n","protected":false},"author":3,"featured_media":547,"comment_status":"closed","ping_status":"closed","sticky":false,"template":"","format":"standard","meta":{"_acf_changed":false,"footnotes":""},"categories":[53,54],"tags":[56,58,57],"class_list":["post-607","post","type-post","status-publish","format-standard","has-post-thumbnail","hentry","category-news","category-studies","tag-ovarian-cancer","tag-results","tag-study"],"acf":[],"_links":{"self":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/607","targetHints":{"allow":["GET"]}}],"collection":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts"}],"about":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/types\/post"}],"author":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/users\/3"}],"replies":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/comments?post=607"}],"version-history":[{"count":1,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/607\/revisions"}],"predecessor-version":[{"id":608,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/posts\/607\/revisions\/608"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/media\/547"}],"wp:attachment":[{"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/media?parent=607"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/categories?post=607"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/studienportal-gyn.de\/en\/wp-json\/wp\/v2\/tags?post=607"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}